Incyte Corp

Latest Results (12.11.2025):

Incyte Corp reported its financial results for the second quarter of 2024 with notable progress. Total revenues grew 9% year-over-year, supported by strong performance in key products such as Jakafi® and Opzelura®. The report highlighted increased patient demand and expanding payer coverage, alongside strategic updates to its pipeline and corporate actions including significant share repurchases and acquisitions.

Financial Performance

Total revenues grew by 9% year-over-year in Q2 2024. Jakafi® showed a 9% increase in paid demand despite slightly lower net revenue growth due to adjustments in channel inventory levels. Meanwhile, Opzelura® benefited from robust patient demand and expanded payer coverage, with European revenues reaching $11 million and full reimbursement achieved or upcoming in key markets.

Pipeline and Clinical Developments

Incyte’s Q2 2024 report emphasized updates across its clinical portfolio. Noteworthy are the Phase 3 studies for retifanlimab (Zynyz®) in squamous cell anal carcinoma and non-small cell lung cancer, which met their primary endpoints. Additionally, the company’s ongoing studies in myeloproliferative neoplasms, GVHD, and multiple dermatological indications underscore its commitment to advancing innovative therapies.

Corporate and Strategic Actions

During the quarter, Incyte Corp repurchased approximately 33.3 million shares at $60.00 per share, totaling nearly $2.0 billion, and completed the acquisition of Escient Pharmaceuticals to boost its clinical-stage portfolio. The company also entered a collaboration with China Medical System Holdings Limited to develop povorcitinib in multiple Asian markets, reinforcing its strategic focus on high-impact programs.